Ultragenyx Pharmaceutical
RARE
158 hedge funds and large institutions have $3.75B invested in Ultragenyx Pharmaceutical in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 54 increasing their positions, 57 reducing their positions, and 27 closing their positions.
50% more capital invested
Capital invested by funds: $2.5B → $3.75B (+$1.25B)
0.58% less ownership
Funds ownership: 98.65% → 98.07% (-0.58%)
5% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 57
7% less call options, than puts
Call options by funds: $13.2M | Put options by funds: $14.2M
4% less funds holding
Funds holding: 165 → 158 (-7)
19% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$35.2M |
| 2 |
Alkeon Capital Management
New York
|
+$31.7M |
| 3 |
HCM
Highline Capital Management
New York
|
+$26.5M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$26.4M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.4M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$28.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$23.8M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$19.1M |
| 5 |
Goldman Sachs
New York
|
-$18.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
176
Covington Capital Management
Los Angeles,
California
| – | -$102K | -2,000 | Closed |
|
|
CLM
177
ClearBridge LLC (Maryland)
Baltimore,
Maryland
| – | -$56K | -1,097 | Closed |
|
|
AI
178
ArchPoint Investors
Coral Gables,
Florida
| – | -$51K | -1,000 | Closed |
|
|
NIT
179
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$10K | -200 | Closed |
|
|
KF
180
Krilogy Financial
St. Louis,
Missouri
| – | -$5K | -100 | Closed |
|
|
PWM
181
Perigon Wealth Management
San Francisco,
California
| – | -$5K | -100 | Closed |
|
182
SEI Investments
Oaks,
Pennsylvania
| – | -$194 | -3 | -33% |
|
RARE Hedge Fund Activity: Q2 2018 in Review
158 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2018, worth a combined $3.75B — up 50% from $2.5B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of RARE and 22 opened new positions — a net loss of 5 holders — while 57 trimmed existing stakes and 54 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $35.2M. The largest seller was Fidelity Investments, cutting an estimated $31.4M.
- 158 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2018, down from 165 in Q1 2018.
- Funds reported $3.75B of Ultragenyx Pharmaceutical stock for Q2 2018, up 50% quarter-over-quarter.
- 22 funds opened new Ultragenyx Pharmaceutical positions in Q2 2018 and 27 closed out, a net change of -5 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2018 was T. Rowe Price Associates, an estimated $35.2M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2018 was Fidelity Investments, an estimated $31.4M sold.
Based on aggregated 13F filings for Q2 2018.